CLOSE X

COHANCE LIFESCIENCES LTD.

NSE : COHANCEBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE921.05-10.55 (-1.13 %)
PREV CLOSE ( ) 931.60
OPEN PRICE ( ) 972.00
BID PRICE (QTY) 919.65 (1)
OFFER PRICE (QTY) 920.90 (2)
VOLUME 1096
TODAY'S LOW / HIGH ( )911.00 972.00
52 WK LOW / HIGH ( )919.55 1359
NSE922.05-11.05 (-1.18 %)
PREV CLOSE( ) 933.10
OPEN PRICE ( ) 930.00
BID PRICE (QTY) 921.45 (4)
OFFER PRICE (QTY) 922.05 (13)
VOLUME 23855
TODAY'S LOW / HIGH( ) 910.75 933.00
52 WK LOW / HIGH ( )915.75 1360
GO
(Rs.in Million)
Particulars
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
4020.20
3071.50
2577.20
2306.90
Total Expenditure
3284.60
1894.50
1537.10
1507.60
PBIDT (Excl OI)
735.60
1177.00
1040.10
799.30
Other Income
105.70
157.10
141.20
181.60
Operating Profit
841.30
1334.10
1181.30
980.90
Interest
57.50
33.30
16.70
16.00
Exceptional Items
NA
NA
NA
NA
PBDT
783.80
1300.80
1164.60
964.90
Depreciation
267.80
203.50
169.60
134.00
Profit Before Tax
516.00
1097.30
995.00
830.90
Tax
128.70
264.40
175.20
223.20
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
387.30
832.90
819.80
607.70
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
387.30
832.90
819.80
607.70
Minority Interest
32.80
-4.10
2.30
NA
Shares of Associates
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
420.10
828.80
822.10
607.70
Equity Capital
254.60
254.60
254.60
254.60
Face Value (IN RS)
1.00
1.00
1.00
1.00
Reserves
NA
NA
NA
NA
Calculated EPS
1.65
3.26
3.23
2.39
Calculated EPS (Annualised)
6.60
13.02
12.92
9.55
No of Public Share Holdings
127025364.00
127025364.00
127025364.00
127025364.00
% of Public Share Holdings
49.90
49.90
49.90
49.90
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
18.30
38.32
40.36
34.65
PBIDTM%
20.93
43.43
45.84
42.52
PBDTM%
19.50
42.35
45.19
41.83
PBTM%
12.84
35.73
38.61
36.02
PATM%
9.63
27.12
31.81
26.34
 
Notes
Notes
Notes
Notes
ATTENTION INVESTORS NSDL/CDSL KYC Advisory for investors